关键词: AASLD AFP ALT APASL American Association for the Study of Liver Diseases Antiviral Therapy Asian Pacific Association for the Study of the Liver CHB Chronic Hepatitis B EASL European Association for the Study of the Liver HBV HBeAg HBsAg HCC Hepatitis B Guidelines IFN Management NUC PEG-IFN ULN alanine aminotransferase anti-HBc anti-HBe chronic hepatitis B hepatitis B core antibody hepatitis B e antibody hepatitis B e antigen hepatitis B surface antigen hepatitis B virus hepatocellular carcinoma interferon nucleos(t)ide analogue pegylated-interferon upper limit of normal α-fetoprotein

Mesh : Antiviral Agents / therapeutic use Hepatitis B, Chronic / diagnosis drug therapy Humans Practice Guidelines as Topic

来  源:   DOI:10.1016/j.cgh.2013.04.036   PDF(Sci-hub)

Abstract:
Seven drugs have been approved for the treatment of chronic hepatitis B. Antiviral treatment has been shown to be effective in suppressing hepatitis B virus replication, decreasing inflammation and fibrosis in the liver, and preventing progression of liver disease. However, current medications do not eradicate hepatitis B virus; therefore, a key question is which patients need to start treatment and which patients can be monitored. Professional societies have developed guidelines to assist physicians in recognition, diagnosis, and optimal management of patients with chronic hepatitis B. These guidelines suggest preferred approaches, and physicians are expected to exercise clinical judgment to determine the most appropriate management based on the circumstances of the individual patient. This article reviews recommendations in hepatitis B guidelines and the basis for those recommendations, and we discuss what we do in our practice to illustrate factors that may influence decisions regarding hepatitis B management.
摘要:
暂无翻译
公众号